Cardio Diagnostics (CDIO): customer footprint, contracts and commercial levers investors should track

Cardio Diagnostics monetizes by selling epigenetics‑based clinical tests and related software and services to healthcare providers, employers and direct‑to‑consumer channels; revenue is recognized primarily via per‑test invoicing and negotiated provider or employer contracts, supplemented by subscription and software offerings. The company is in early commercial rollout—domestic community partnerships and an initial India expansion drive top‑line growth while diagnostics lab operations and reimbursement milestones determine scalability and margin expansion.

If you want a concise commercial diligence brief tailored for deal teams and investors, visit https://nullexposure.com/ for more firm‑level intelligence.

How the business actually contracts and where revenue comes from

Cardio Diagnostics sells a product suite composed of clinical tests (Epi+Gen CHD™, PrecisionCHD™), a software platform (HeartRisk™) and a research service (CardioInnovate360™). Revenue flows through two principal commercial mechanisms:

• Usage‑based invoicing: provider organizations, telemedicine firms and employers are billed for tests performed, with monthly invoicing for completed samples or completed testing cycles. This is the primary revenue-recognition mechanics described in company disclosures.
• Subscription and software licensing: concierge practices and certain employers can adopt subscription arrangements or license HeartRisk™, targeting preventive and population‑health use cases.

These contracting modes produce a mixed posture: highly negotiable, per‑counterparty pricing with monthly settlements, and occasional subscriptions for higher‑touch customers. Counterparty mix signals include small businesses (concierge practices), individuals (patient payors), and large enterprises (self‑insured employers). The firm classifies customers as buyers across provider, employer and telemedicine channels and signals an active relationship stage focus on customer service and retention.

Operationally this implies low revenue concentration tolerance but high operational criticality — labs must deliver consistent quality control, reporting and turnaround to convert pilots into repeated, scalable volume. Financially, the company is early stage: RevenueTTM $14,820, negative EBITDA and a small market cap, reflecting first commercial contracts and an emphasis on customer acquisition over profitability.

What the relationship data shows — partner‑by‑partner read

Below are every customer relationship noted in the monitored results, each with a plain‑English summary and source reference.

Dr. Lal PathLabs — MPO Magazine report (FY2026)

Cardio Diagnostics began an integration and promotion phase with Dr. Lal PathLabs to align the PrecisionCHD test with Indian clinical and regulatory protocols as part of a commercial rollout. According to MPO Magazine reporting in March 2026, the partnership is focused on deployment within Dr. Lal’s laboratory and clinical network.

Centers for Medicare and Medicaid Services (CMS) — Investing.com filing mention (FY2025)

CMS issued preliminary gap‑fill payment rates for two of Cardio Diagnostics’ cardiovascular tests, signaling steps toward formal reimbursement pathways that materially affect U.S. commercial economics. This regulatory development was noted in a company filing reported by Investing.com in 2026.

Dr. Lal PathLabs — Houston Business Journal coverage (FY2026)

Cardio Diagnostics confirmed a partnership with Dr. Lal PathLabs, which has an extensive Indian lab footprint; the CEO framed the partner as a channel to scale PrecisionCHD across an established clinical network. The Houston Business Journal covered this expansion in January 2026.

LALPATHLAB — Markets/FinancialContent BizWire release (FY2026)

A BizWire release described the initial phase of the Dr. Lal PathLabs partnership and emphasized integration and promotion of the PrecisionCHD test within Dr. Lal’s extensive clinical network. The press release (Jan 2026) reiterates the company’s India market entry strategy.

Southdale YMCA — PennWell/WaterWorld BizWire release (FY2026)

Cardio Diagnostics announced a partnership with the Southdale YMCA to provide heart‑health education and advanced cardiovascular testing to members and the Edina, Minnesota community, reflecting community‑level channel experiments. The partnership was publicized in the company’s January 2026 announcement.

YMCA of East Tennessee — PennWell/WaterWorld BizWire release (FY2026)

The company referenced its inaugural YMCA partnership in East Tennessee when announcing the Southdale YMCA collaboration, signaling a repeatable local outreach model for community screening and awareness. This follow‑on history was included in the same January 2026 release.

Dr. Lal PathLabs (alternate BizJournals Seattle article) — Seattle BizJournals (FY2026)

An expanded Seattle Business Journal article states Dr. Lal PathLabs agreed to integrate and promote the test and is expected to ramp up commercial rollout in 2026, providing consistency across regional reporting on execution timing.

Dr. Lal PathLabs — Investing.com market news (FY2025)

Investing.com noted the initial phase of the Dr. Lal PathLabs partnership beginning with protocol alignment and integration, reported alongside Cardio Diagnostics’ broader strategic updates in 2026.

Aimil Ltd — TradingView investor‑call summary (FY2026)

Cardio Diagnostics announced an international partnership in India with Aimil Ltd alongside Dr. Lal PathLabs to introduce PrecisionCHD and explore broader global expansion opportunities; TradingView summarized this on the company investor call in early 2026.

Dr. Lal PathLabs — TradingView investor‑call summary (FY2026)

The same investor‑call materials summarized by TradingView reiterated the Aimil/Dr. Lal PathLabs collaboration to introduce PrecisionCHD, underscoring management’s emphasis on India as the first international commercial market.

Aimil Ltd — Houston Business Journal coverage (FY2026)

Houston Business Journal noted Aimil Ltd’s institutional history in India and its role in the announced partnership, framing Aimil as a local distribution and channel partner referenced by Cardio Diagnostics’ CEO in January 2026.

What these relationships imply for investors

• Commercial testing is the core revenue engine: most relationships are distribution or channel agreements to deploy PrecisionCHD and allied tests, not equity or large OEM deals. That means growth is volume‑driven and tied to lab throughput and provider adoption.
• Reimbursement is the critical gating factor: CMS gap‑fill activity directly affects pricing and adoption in the U.S.; favorable reimbursement unlocks employer and health‑system contracts at scale.
• International expansion is execution‑heavy but de‑risked via local partners: partnerships with Dr. Lal PathLabs and Aimil Ltd transfer market access risk but require regulatory integration and local commercial cadence.
• Community partnerships (YMCA) illustrate demand generation tactics: these are low‑margin, visibility‑focused pilots intended to generate sample volume and awareness.

Constraints and company‑level signals that shape commercial risk

• Contracting posture blends usage‑based billing with subscription elements, indicating predictable monthly invoicing but variable per‑test revenue tied to volume and customer negotiation.
• Counterparty mix spans small business (concierge practices), individuals (patient payors), and large enterprises (self‑insured employers), creating diversified go‑to‑market channels but also higher sales complexity.
• Relationship role is primarily buyer (providers, employers, telemedicine firms) and the company flags active customer engagement as essential to retention.
• Product segmentation is clear: clinical tests are the core product, CardioInnovate360™ is a services/research offering and HeartRisk™ is the software play, implying multiple monetization levers as adoption broadens.

Bottom line — what to watch next

Track three measurable indicators: test volume growth and lab throughput, CMS reimbursement decisions and timelines, and ramp metrics from Dr. Lal PathLabs/Aimil in India. Those three variables determine whether CDIO transitions from pilot revenues (RevenueTTM $14,820) to scalable, recurring cash flows.

For a compact commercial diligence pack and on‑demand partner mapping, see https://nullexposure.com/.